CA3006291A1 - Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease - Google Patents
Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease Download PDFInfo
- Publication number
- CA3006291A1 CA3006291A1 CA3006291A CA3006291A CA3006291A1 CA 3006291 A1 CA3006291 A1 CA 3006291A1 CA 3006291 A CA3006291 A CA 3006291A CA 3006291 A CA3006291 A CA 3006291A CA 3006291 A1 CA3006291 A1 CA 3006291A1
- Authority
- CA
- Canada
- Prior art keywords
- treatment
- alx
- fpr2
- compound
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259498P | 2015-11-24 | 2015-11-24 | |
| US62/259,498 | 2015-11-24 | ||
| PCT/US2016/063036 WO2017091496A1 (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3006291A1 true CA3006291A1 (en) | 2017-06-01 |
Family
ID=57544530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3006291A Abandoned CA3006291A1 (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180325869A1 (enExample) |
| EP (1) | EP3380091A1 (enExample) |
| JP (1) | JP2018538367A (enExample) |
| KR (1) | KR20180081528A (enExample) |
| CN (1) | CN108348479A (enExample) |
| AU (1) | AU2016359463A1 (enExample) |
| BR (1) | BR112018010155A8 (enExample) |
| CA (1) | CA3006291A1 (enExample) |
| EA (1) | EA201891007A1 (enExample) |
| IL (1) | IL259468A (enExample) |
| MX (1) | MX2018005756A (enExample) |
| SG (1) | SG11201803816RA (enExample) |
| WO (1) | WO2017091496A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3414227B1 (en) | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227067A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110997653B (zh) | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
| US11008301B2 (en) | 2017-06-09 | 2021-05-18 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US10676431B2 (en) | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| IL299680A (en) | 2020-07-09 | 2023-03-01 | Bristol Myers Squibb Co | Pyrazolone formyl peptide 2 receptor agonists |
| JP7802765B2 (ja) | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2492167C2 (ru) * | 2007-12-18 | 2013-09-10 | Актелион Фармасьютиклз Лтд | Производные аминотриазола в качестве агонистов alх |
| KR101905927B1 (ko) * | 2010-11-17 | 2018-10-08 | 이도르시아 파마슈티컬스 리미티드 | 가교된 스피로［２．４］헵탄 에스테르 유도체 |
| CA2871334A1 (en) * | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| EP3414227B1 (en) * | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| US10676431B2 (en) * | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
-
2016
- 2016-11-21 CN CN201680068442.7A patent/CN108348479A/zh active Pending
- 2016-11-21 WO PCT/US2016/063036 patent/WO2017091496A1/en not_active Ceased
- 2016-11-21 MX MX2018005756A patent/MX2018005756A/es unknown
- 2016-11-21 AU AU2016359463A patent/AU2016359463A1/en not_active Abandoned
- 2016-11-21 EA EA201891007A patent/EA201891007A1/ru unknown
- 2016-11-21 EP EP16810536.9A patent/EP3380091A1/en not_active Withdrawn
- 2016-11-21 JP JP2018545568A patent/JP2018538367A/ja not_active Withdrawn
- 2016-11-21 KR KR1020187014477A patent/KR20180081528A/ko not_active Withdrawn
- 2016-11-21 BR BR112018010155A patent/BR112018010155A8/pt not_active Application Discontinuation
- 2016-11-21 CA CA3006291A patent/CA3006291A1/en not_active Abandoned
- 2016-11-21 US US15/776,927 patent/US20180325869A1/en not_active Abandoned
- 2016-11-21 SG SG11201803816RA patent/SG11201803816RA/en unknown
-
2018
- 2018-05-17 IL IL259468A patent/IL259468A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180325869A1 (en) | 2018-11-15 |
| KR20180081528A (ko) | 2018-07-16 |
| EP3380091A1 (en) | 2018-10-03 |
| BR112018010155A8 (pt) | 2019-02-26 |
| WO2017091496A1 (en) | 2017-06-01 |
| SG11201803816RA (en) | 2018-06-28 |
| MX2018005756A (es) | 2018-08-01 |
| CN108348479A (zh) | 2018-07-31 |
| IL259468A (en) | 2018-07-31 |
| JP2018538367A (ja) | 2018-12-27 |
| EA201891007A1 (ru) | 2018-11-30 |
| AU2016359463A1 (en) | 2018-07-12 |
| BR112018010155A2 (pt) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3006291A1 (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| US11873266B2 (en) | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | |
| JP5707489B2 (ja) | １型糖尿病の処置 | |
| JP7508496B2 (ja) | 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド | |
| US20200069644A1 (en) | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure | |
| AU2014262764B2 (en) | Radiomitigating pharmaceutical formulations | |
| KR102354243B1 (ko) | 트롬복산-a2 수용체 길항제를 이용한 근위축증 치료 조성물 및 방법 | |
| EA018898B1 (ru) | Способ лечения амилоидоза | |
| AU2017342551B2 (en) | Methods of treatment and pharmaceutical compositions using BCN057 or BCN512 | |
| PT1587584E (pt) | Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais | |
| CN108472333B (zh) | 组合 | |
| JP6688503B2 (ja) | 医薬用組成物 | |
| US20230114408A1 (en) | Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists | |
| KR20220143059A (ko) | 섬유증의 치료를 위한 시클로스포린 유사체의 용도 | |
| US10799511B2 (en) | Methods for reducing or ameliorating mortality and/or morbidity due to chlorine inhalation | |
| WO2026064493A1 (en) | Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure | |
| WO2026057747A1 (en) | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds | |
| HK40080138A (en) | Methods of modulating t-cell activation using carboranes and carborane analogs | |
| CN115515580A (zh) | 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法 | |
| HK1208363B (en) | Compounds for use in the treatment of aquaporin-mediated diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20210831 |